12:00 AM
Mar 23, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ATB-346: Development resumed

Antibe resumed development of ATB-346 following collection and review of data from a double-blind, placebo-controlled, Canadian Phase I trial evaluating single and multiple ascending doses of oral ATB-346 in healthy volunteers. The company suspended the...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >